Active Ingredient(s): Gadoterate Meglumine
FDA Approved: * March 20, 2013
Pharm Company: * GUERBET
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Dotarem Overview

Gadoteric acid, sold under the brand name Dotarem among others, is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA). It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt (gadoterate meglumine).[3] The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical utility. Because it ha...

Read more Dotarem Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Dotarem Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Gadoterate Meglumine
  • Injection: 0.5mmol/ml
  • Solution: 1.8845gm/5ml (376.9mg/ml), 1.884gm/5ml (376.9mg/ml), 3.769gm/10ml (376.9mg/ml), 37.69gm/100ml (376.9mg/ml), 5.6535gm/15ml (376.9mg/ml), 7.538gm/20ml (376.9mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Dotarem: (3 results)

Sorted by National Drug Code
  • 67684-2000 Dotarem 376.9 mg/ml Intravenous Injection by Guerbet LLC
  • 67684-2001 Dotarem 376.9 mg/ml Intravenous Injection by Guerbet LLC
  • 67684-3001 Dotarem 376.9 mg/ml Intravenous Injection by Guerbet LLC

Other drugs which contain Gadoterate Meglumine or a similar ingredient: (2 results)